LIfT BioSciences presents latest data on its first-in-class Immunomodulatory Alpha Neutrophils at International Society for Cell and Gene Therapy

LIfT BioSciences presents latest data on its first-in-class Immunomodulatory Alpha Neutrophils at International Society for Cell and Gene Therapy

London, 19 May 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces that preclinical data showing the potential of its first-in-class Immunomodulatory Alpha Neutrophils (IMANs) as a disruptive new class of immunotherapy for solid tumours was presented at the International Society for Cell and Gene Therapy (ISCT) 2025 New Orleans Annual Meeting held from 7-10 May.

The poster highlights significant advancements in the therapeutic performance of IMANs, with data showcasing IMANs’ dual mechanism of action, combining direct tumour cytotoxicity with potent immunomodulatory effects in solid tumours.

Key highlights include:

• IMAN immunotherapy demonstrates superior tumour penetration and direct cancer cell killing: IMANs, whether haematopoietic stem cell- or induced pluripotent stem cell-derived, demonstrated exceptional anti-cancer properties across multiple solid tumour types. Data shows IMANs rapidly infiltrate tumours, with superior killing capabilities against patient-derived tumour organoids from non-small cell lung cancer, bladder, pancreatic, and colorectal cancers. Unlike conventional immunotherapies that focus solely on adaptive immunity and fixed targets, IMANs offer a comprehensive approach that addresses the fundamental challenge of immunosuppressive tumour microenvironments.
  
  
• Dual-action mechanism transforms immunologically "cold" tumours "hot” and activates systemic anti-cancer immunity: In vitro and in vivo studies demonstrated that IMANs effectively infiltrate tumours and reprogramme the tumour microenvironment (TME), converting "cold” tumours into immune-responsive "hot” tumours. IMANs demonstrate a unique dual mechanism of action that addresses key challenges in solid tumour immunotherapy, with tumour models demonstrating that IMANs not only directly kill cancer cells, but also significantly enhance the tumour microenvironment through powerful immunomodulatory effects: secreting critical cytokines, while dramatically increasing CD8+ T cell activation markers and promoting complete survival of NK cells in co-culture experiments. In humanised models, this translated to persistent tumour infiltration for over 21 days and recruitment of NK cells to the tumour site, potentially establishing long-lasting anti-cancer immunity where previous approaches have failed.
  
  

Poster presentation:

1. Presentation title: ‘IMANS: A Transformative Solution for Overcoming Challenges of Solid Tumour Immunotherapy and Rejuvinating Innate Immunity, With Broad Implications for Oncology and Beyond
   
   

Presenter: Mark A. Exley, Chief Scientific Officer, LIfT BioSciences

The poster can be found here.

Alex Blyth, Chief Executive Officer of LIfT BioSciences, commented: "We are pleased share our latest preclinical data with the scientific community at the ISCT Annual Meeting. Through our scalable, GMP-compliant manufacturing process enabling the production of high-quality IMANs, the data reinforces the transformative potential of IMANs as a disruptive new class of immunotherapy for solid tumours. The dual anti-tumour mechanisms, combining direct cytotoxic activity with immunomodulation of the solid tumour microenvironment, rejuvenates the innate immune system and drives a durable immune response, offering hope for a more effective and accessible cancer treatment, particularly in tumours where current therapies fall short. These findings represent an important step forward as we continue to advance our IMANs toward the clinic and help shape the future of immunotherapy.”

About LIfT BioSciences
LIfT Biosciences is a UK & Ireland biotech that is bringing to market a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) kill in a non-antigen specific manner and turn the tumour microenvironment against the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering.

The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered IMAN immunotherapies to destroy a range of solid tumours. See www.LIfTBiosciences.com

Further information
Investors:
Alex Blyth
ablyth@LIfTBioSciences.com

Media:
ICR Healthcare
Lindsey Neville, Namrata Taak, Evi Useh
liftbiosciences@icrhealthcare.com